Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A

Core Viewpoint - Resverlogix Corp. is experiencing delays in completing its year-end audit, which will prevent the company from meeting the March 31, 2026 deadline for filing its Annual Filings [1] Group 1: Audit and Filing Delays - The company anticipates it will not meet the March 31, 2026 deadline for filing Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year ended December 31, 2025 [1] - The auditor has indicated that the audit of the annual financial statements is unlikely to be completed by the deadline, with an expected completion date of April 10, 2026 [1] Group 2: Management Cease Trade Order - Resverlogix has applied to the Alberta Securities Commission for a management cease trade order (MCTO) that would restrict the trading of the company's securities by its CEO and CFO until the Annual Filings are submitted [2] - The ASC has not yet made a decision on the MCTO application, which could either be granted or result in an issuer cease trade order if delays continue [2] Group 3: Compliance and Reporting - The company is committed to completing the Annual Filings as soon as possible and will issue a news release once they are filed [3] - Until the Annual Filings are submitted, the company will adhere to guidelines set out in NP 12-203, including bi-weekly default status reports [3] Group 4: Insider Trading Blackout - Members of the company's management and other insiders are subject to an insider trading blackout until the Annual Filings are completed [4] - There have been no material business developments since the interim financial reports were filed on November 13, 2025 [4] Group 5: Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases [5] - The company is a leader in epigenetics and is developing a new class of therapies aimed at regulating disease-causing gene expression, particularly focusing on cardiovascular disease and post COVID-19 conditions [6]